Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA

FDA's draft guidance on patient-reported outcomes (PROs) should offer both greater flexibility and detail, industry commenters told the agency

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet